Ashley Gallagher, Editor

Convalescent plasma, IVIG, and remdesivir have successfully helped immunocompromised patients recover from the virus.

The results of a new study show that stopping jailing individuals may be linked to benefits to community-wide and global public health.

New evidence shows that moving to urban areas in the Midwest or either coast could increase the longevity of an individual’s life.

Research shows that individuals who had either a severe or mild case of the virus had an increased risk of kidney damage and disease.

Study shows the benefit of green and blue spaces for individuals with COPD living in urban communities.

The results of a recent Aging-US study show that these additives provide anti-inflammatory and neuroprotective glial subpopulation benefits.

Following a phase 2 study, Moderna submitted initial data to the FDA for the approval of its COVID-19 booster shot that would be administered 6 months after an individual’s second dose.

A study found individuals receiving probiotics had a decrease in C. difficile diagnosed in stool samples than those who did not receive probiotics.

Umeā University in Sweden finds a connection between the two, due to the intestinal micobiome.

The FDA has approved a second drug, zanubritinib, for the treatment of adult patients with Waldenström’s macroglobulinemia.

Published results indicate that marriage, urban living put people less at risk for cardiovascular problems.

FDA’s green light for biopharmaceutical company’s drug candidate builds upon previous approval to treat pancreatic cancer.

Brigham and Women’s Hospital conducted an analysis to measure the response of T cells from MMR and Tdap vaccines that could help to decrease COVID-19 severity.

St. Jude Children’s Research Hospital reminds parents about the importance of getting the HPV vaccination during National Immunization Awareness Month.

New paper shows that pregnant women often have low iron levels, while 1 in 4 have a severe deficiency.

Pharmaceutical companies continue trial for GBP510 in conjunction with GSK’s pandemic adjuvant.